Article info
Research ethics
On the personal utility of Alzheimer’s disease-related biomarker testing in the research context
- Correspondence to Eline M Bunnik, Department of Medical Ethics and Philosophy of Medicine, Erasmus MC, Rotterdam 3015 GD, The Netherlands; e.bunnik{at}erasmusmc.nl
Citation
On the personal utility of Alzheimer’s disease-related biomarker testing in the research context
Publication history
- Received January 19, 2018
- Revised June 18, 2018
- Accepted August 4, 2018
- First published August 28, 2018.
Online issue publication
November 22, 2018
Article Versions
- Previous version (28 August 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Exploring cognitive and biological correlates of sleep quality and their potential links with Alzheimer’s disease (ALFASleep project): protocol for an observational study
- Personal utility in genomic testing: is there such a thing?
- Retinal imaging in Alzheimer’s disease
- What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France
- New diagnostic criteria for Alzheimer's disease and mild cognitive impairment for the practical neurologist
- Moral motivation regarding dementia risk testing among affected persons in Germany and Israel
- Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic
- Remote data collection speech analysis and prediction of the identification of Alzheimer’s disease biomarkers in people at risk for Alzheimer’s disease dementia: the Speech on the Phone Assessment (SPeAk) prospective observational study protocol
- Two-year outcome of MCI subtypes and aetiologies in the Göteborg MCI study
- Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study